Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levorphanol for Cancer Pain Opioid Rotation
NCT03579446Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2018
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of levorphanol in cancer pain, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Proportion of successful opioid rotation (OR) from morphine equivalent daily dose (MEDD) to levorphanol at Day 10. Started Nov 2018; status: terminated.
02
Drugs
levorphanol
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT03579446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03579446.